Compare RNW & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | EVO |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United Kingdom | Germany |
| Employees | 4336 | 4766 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 821.2M |
| IPO Year | N/A | N/A |
| Metric | RNW | EVO |
|---|---|---|
| Price | $5.28 | $2.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | ★ 620.6K | 110.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.97 | $7.13 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.05 | $2.31 |
| 52 Week High | $8.24 | $4.80 |
| Indicator | RNW | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.86 | 30.14 |
| Support Level | $5.27 | N/A |
| Resistance Level | $5.58 | $3.78 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 32.40 | 13.89 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.